Generic drugs have slower approval route than new ones, backlogged by FDA staff shortage - The Washington Post

Generic drugs go through what the Food and Drug Administration calls an abbreviated approval process. But it takes three times as long as FDA reviews of new experimental drugs because of the sheer volume of applications, many of which are submitted years before the original drug’s patent will expire. Because so many widely used drugs are approaching the end of their patents...